Lymphoma: Clinical Trials

8,390 trials for Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3741 completed, 1159 recruiting, 1125 unknown, 992 terminated. 3697 Phase 2, 2854 Phase 1, 803 Not applicable, 697 Phase 3, 166 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23697Completed 1609, Terminated 505, Recruiting 496, Unknown 464, Active not recruiting 308, Withdrawn 156, Not yet recruiting 141, Suspended 13, Enrolling by invitation 5
Phase 12854Completed 1279, Terminated 434, Recruiting 378, Unknown 295, Active not recruiting 219, Withdrawn 149, Not yet recruiting 79, Suspended 16, Enrolling by invitation 5
Not applicable803Completed 356, Unknown 138, Recruiting 133, Terminated 62, Active not recruiting 39, Not yet recruiting 35, Withdrawn 29, Enrolling by invitation 8, Suspended 3
Phase 3697Completed 323, Unknown 111, Recruiting 85, Terminated 70, Active not recruiting 63, Not yet recruiting 23, Withdrawn 19, Enrolling by invitation 2, Suspended 1
Early Phase 1166Unknown 44, Recruiting 34, Completed 30, Terminated 19, Not yet recruiting 18, Active not recruiting 11, Withdrawn 6, Suspended 4
Phase 4147Completed 63, Unknown 46, Recruiting 16, Terminated 7, Not yet recruiting 6, Active not recruiting 5, Withdrawn 4

Follow Lymphoma: new trials by email Literature Review of Lymphoma trials Research Report on Lymphoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
FLASH Pilot Phase 1 Safety Study
IntraOp Mobetron UHDR, Linac - Cutaneous Lymphoma
Not applicableNot yet recruitingLesley A. Jarvis102029-10-312026-05-27
Family-Focused Study to Support Medication for Opioid Use Disorder
FamilyCHESS, Standard of Care - Opioid Use Disorder, Opioid Use Disorder, Moderate
Not applicableNot yet recruitingUniversity of Wisconsin, Madison3382027-08-312026-07-07
Astragalus for Symptomatic Alleviation in High-grade Lymphoma
Astragalus, Placebo - High-grade Lymphoma
Phase 3Not yet recruitingBnai Zion Medical Center602027-08-012026-09-30
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Phase 1RecruitingNational Cancer Institute (NCI)152027-07-052026-11-05
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
Sugemalimab, Placebo, Pegaspargase - Extranodal NK/T-cell Lymphoma
Phase 3Not yet recruitingCStone Pharmaceuticals1502027-06-012026-05-27
Multi-CAR-T Cells Targeting B Cell Lymphomas
4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL)
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute112027-06-012026-11-02
Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome
Biospecimen Collection, Computed Tomography, Cosibelimab - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome
Phase 1Not yet recruitingCity of Hope Medical Center142027-05-162026-11-09
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL
Phase 2Not yet recruitingAbelZeta Inc.552027-05-012026-10-15
Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma
golcadomide, Obinutuzumab, Polatuzumab - Multi Center, Phase 2
Phase 2Not yet recruitingM.D. Anderson Cancer Center602027-04-292026-11-05
Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma
Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Phase 1RecruitingCity of Hope Medical Center162027-04-172026-11-13
Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.
CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies
Phase 1Not yet recruitingGUSTAVO SALGUERO122027-04-012026-10-20
Molecular and Cellular Characterization of MALT Lymphoma
MALT Lymphoma
Not yet recruitingInternational Extranodal Lymphoma Study Group (IELSG)4002027-04-012026-11-12
Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)
Asciminib, Inotuzumab ozogamicin - B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 1RecruitingSunil G. Iyer452027-03-312026-11-13
Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma
Phase 1RecruitingNational Cancer Institute (NCI)302027-03-262026-10-20
Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial
Polatuzumab Vedotin, Acalabrutinib, Mosunetuzumab - Mantle Cell Lymphoma
Phase 2Not yet recruitingUniversity of Washington272027-03-012026-11-02
Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)
Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma
Phase 1Not yet recruitingUniversity of Chicago322027-02-232026-10-22
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
Epcoritamab, Observation - Randomized, Phase 2
Phase 2Not yet recruitingM.D. Anderson Cancer Center402027-02-122026-11-02
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 1 / Phase 2RecruitingZhujiang Hospital152027-02-012025-03-30
IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas
IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4
Phase 2Not yet recruitingGerman Cancer Research Center2162027-02-012026-10-22
Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia
Fludarabine, Cyclophosphamide, Levetiracetam - CD19 Positive, B-ALL
Phase 1Not yet recruitingMedical University of South Carolina182027-02-012026-11-13

Showing 20 of 8390. Sign in to see all of them.

Narrower conditions

Lymphoma, Non-Hodgkin (2287)  ·  Lymphoma, Follicular (1875)  ·  Lymphoma, Large B-Cell, Diffuse (1831)  ·  Hodgkin Disease (1301)  ·  Lymphoma, Mantle-Cell (1211)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1126)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1025)  ·  Burkitt Lymphoma (977)  ·  Leukemia (883)  ·  Lymphoma, B-Cell, Marginal Zone (865)  ·  Multiple Myeloma (817)  ·  Lymphoma, B-Cell (780)  ·  Recurrence (733)  ·  Leukemia, Myeloid, Acute (603)

Broader conditions

Neoplasms by Histologic Type (8362)  ·  Hemic and Lymphatic Diseases (8308)  ·  Immune System Diseases (8251)  ·  Immunoproliferative Disorders (8249)  ·  Lymphatic Diseases (8244)  ·  Lymphoproliferative Disorders (8178)  ·  Neoplasms (7914)  ·  Lymphoma, Non-Hodgkin (4123)  ·  Hematologic Diseases (2636)  ·  Lymphoma, B-Cell (2337)  ·  Pathological Conditions, Signs and Symptoms (2183)  ·  Pathologic Processes (2052)  ·  Disease Attributes (1859)  ·  Leukemia, Lymphoid (1728)

Interventions

Rituximab (1192)  ·  Cyclophosphamide (1029)  ·  Vincristine (519)  ·  Doxorubicin (507)  ·  Prednisone (454)  ·  Etoposide (447)  ·  fludarabine (329)  ·  Cytarabine (308)  ·  Lenalidomide (291)  ·  fludarabine phosphate (284)  ·  Filgrastim (282)  ·  Methotrexate (263)  ·  Dexamethasone (251)  ·  Radiotherapy (229)  ·  Bendamustine Hydrochloride (219)

Sponsors

National Cancer Institute (NCI) (411)  ·  M.D. Anderson Cancer Center (268)  ·  Memorial Sloan Kettering Cancer Center (179)  ·  Fred Hutchinson Cancer Center (114)  ·  City of Hope Medical Center (106)  ·  Ruijin Hospital (97)  ·  Hoffmann-La Roche (89)  ·  Novartis Pharmaceuticals (76)  ·  Fondazione Italiana Linfomi - ETS (72)  ·  Celgene (66)  ·  Mayo Clinic (64)  ·  St. Jude Children's Research Hospital (61)  ·  Sun Yat-sen University (59)  ·  Children's Oncology Group (57)  ·  Dana-Farber Cancer Institute (55)

Countries

United States (4482)  ·  China (1374)  ·  France (778)  ·  Italy (639)  ·  United Kingdom (551)  ·  Germany (512)  ·  Canada (511)  ·  Spain (509)  ·  Australia (410)  ·  South Korea (365)  ·  Belgium (298)  ·  Poland (273)  ·  Japan (230)  ·  Netherlands (222)  ·  Israel (196)

Top investigators

Ajay Gopal (16)

Results publications

PMID 34515338, PMID 41671463, PMID 40135712, PMID 32632956, PMID 32499241, PMID 35622074, PMID 31401903, PMID 40550489, PMID 39319495, PMID 26373676, PMID 37505794, PMID 27282998, PMID 40802906, PMID 23834234, PMID 30125215, PMID 31050355, PMID 32816215, PMID 34398557, PMID 35787017, PMID 19238148, PMID 32770353, PMID 33288485, PMID 33883258, PMID 34780125, PMID 34806163, PMID 39563886, PMID 39813680, PMID 17242396, PMID 20660832, PMID 20679620, PMID 21403127, PMID 22430088, PMID 22510871, PMID 23065508, PMID 23524640, PMID 23753028, PMID 25113753, PMID 25381051, PMID 27209293, PMID 28054442, PMID 30010775, PMID 30518502, PMID 30620669, PMID 30770362, PMID 31196847, PMID 32589970, PMID 32596842, PMID 32705923, PMID 32823563, PMID 33795208

NIH funding

2023 (80), P30CA033572 (77), P30CA015704 (58), 2015 (49), 2017 (45), 2016 (43), U10CA180820 (43), U10CA032102 (41), 2018 (38), 2014 (32), P30CA043703 (32), P30CA015083 (31), U10CA031946 (30), U10CA180886 (29), P30CA016672 (28)